Silence Therapeutics

Silence Therapeutics is a London-based biotechnology company whose RNA-therapeutics business was founded in 1999. It develops investigational small interfering RNA medicines using its mRNAi GOLD platform to reduce disease-associated protein production. Its pipeline includes divesiran for polycythemia vera and zerlasiran targeting elevated lipoprotein(a). In October 2026, the company agreed to be acquired by Merck KGaA; completion remained subject to approvals and other conditions.